Nabywcy leków na HIV uznają ofertę zwolnienia Gilead za „nic nowego”

By Dorothy Atkins (February 10, 2023, 6:49 PM EST) -- A proposed class of consumers slammed Gilead Sciences Inc.'s latest bid to end litigation accusing the biopharmaceutical company of paying off generic HIV drugmakers to delay market entry, telling a California federal judge Friday that Gilead is rehashing old arguments the court previously rejected and that "there's nothing new here."...